Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Change in Acquisitions & Divestments: 2020-2022

Historic Change in Acquisitions & Divestments for Apellis Pharmaceuticals (APLS) over the last 3 years, with Dec 2022 value amounting to $393.3 million.

  • Apellis Pharmaceuticals' Change in Acquisitions & Divestments rose 47.04% to $125.0 million in Q4 2022 from the same period last year, while for Dec 2022 it was $393.3 million, marking a year-over-year decrease of 6.36%. This contributed to the annual value of $393.3 million for FY2022, which is 6.36% down from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Change in Acquisitions & Divestments of $393.3 million as of FY2022, which was down 6.36% from $420.0 million recorded in FY2021.
  • Apellis Pharmaceuticals' Change in Acquisitions & Divestments' 5-year high stood at $567.5 million during FY2020, with a 5-year trough of $393.3 million in FY2022.
  • In the last 3 years, Apellis Pharmaceuticals' Change in Acquisitions & Divestments had a median value of $420.0 million in 2021 and averaged $460.3 million.
  • Data for Apellis Pharmaceuticals' Change in Acquisitions & Divestments shows a maximum YoY fell of 25.99% (in 2021) over the last 5 years.
  • Apellis Pharmaceuticals' Change in Acquisitions & Divestments (Yearly) stood at $567.5 million in 2020, then dropped by 25.99% to $420.0 million in 2021, then declined by 6.36% to $393.3 million in 2022.